Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Ketamine and phencyclidine: the good, the bad and the unexpected
David Lodge, Marion Mercier
British Journal of Pharmacology (2015) Vol. 172, Iss. 17, pp. 4254-4276
Open Access | Times Cited: 166

Showing 1-25 of 166 citing articles:

Circuits and functions of the lateral habenula in health and in disease
Hailan Hu, Yihui Cui, Yan Yang
Nature reviews. Neuroscience (2020) Vol. 21, Iss. 5, pp. 277-295
Closed Access | Times Cited: 366
The origin of NMDA receptor hypofunction in schizophrenia
Kazu Nakazawa, Kiran Sapkota
Pharmacology & Therapeutics (2019) Vol. 205, pp. 107426-107426
Open Access | Times Cited: 226
An Overview of Animal Models Related to Schizophrenia
Ian R. Winship, Serdar Dursun, Glen B. Baker, et al.
The Canadian Journal of Psychiatry (2018) Vol. 64, Iss. 1, pp. 5-17
Open Access | Times Cited: 203
A historical review of antidepressant effects of ketamine and its enantiomers
Wei Yan, Lijia Chang, Kenji Hashimoto
Pharmacology Biochemistry and Behavior (2020) Vol. 190, pp. 172870-172870
Open Access | Times Cited: 140
KETAMINE FOR TREATMENT-RESISTANT UNIPOLAR AND BIPOLAR MAJOR DEPRESSION: CRITICAL REVIEW AND IMPLICATIONS FOR CLINICAL PRACTICE
William V. Bobo, Jennifer L. Vande Voort, Paul E. Croarkin, et al.
Depression and Anxiety (2016) Vol. 33, Iss. 8, pp. 698-710
Open Access | Times Cited: 115
Spatial and temporal boundaries of NMDA receptor hypofunction leading to schizophrenia
Kazu Nakazawa, Vivek Jeevakumar, Kazuhito Nakao
Schizophrenia (2017) Vol. 3, Iss. 1
Open Access | Times Cited: 98
Autoimmune synaptopathies
Sarah Crisp, Dimitri M. Kullmann, Angela Vincent
Nature reviews. Neuroscience (2016) Vol. 17, Iss. 2, pp. 103-117
Closed Access | Times Cited: 89
Comparison of R-ketamine and rapastinel antidepressant effects in the social defeat stress model of depression
Bangkun Yang, Jichun Zhang, Mei Han, et al.
Psychopharmacology (2016) Vol. 233, Iss. 19-20, pp. 3647-3657
Open Access | Times Cited: 88
Glutamate in schizophrenia: Neurodevelopmental perspectives and drug development
Alice Egerton, Anthony A. Grace, James Stone, et al.
Schizophrenia Research (2020) Vol. 223, pp. 59-70
Open Access | Times Cited: 83
Comprehensive assessment of side effects associated with a single dose of ketamine in treatment-resistant depression
Elia E. Acevedo-Diaz, Grace W. Cavanaugh, Dede Greenstein, et al.
Journal of Affective Disorders (2019) Vol. 263, pp. 568-575
Open Access | Times Cited: 81
Structural insights into binding of therapeutic channel blockers in NMDA receptors
Tsung‐Han Chou, Max Epstein, Kevin Michalski, et al.
Nature Structural & Molecular Biology (2022) Vol. 29, Iss. 6, pp. 507-518
Open Access | Times Cited: 44
The abuse liability of ketamine: A scoping review of preclinical and clinical studies
Tuyen T. Le, Isabel Pazos Cordero, Muhammad Youshay Jawad, et al.
Journal of Psychiatric Research (2022) Vol. 151, pp. 476-496
Closed Access | Times Cited: 43
GluN3A excitatory glycine receptors control adult cortical and amygdalar circuits
Simon Bossi, Dhanasak Dhanasobhon, Graham C. R. Ellis‐Davies, et al.
Neuron (2022) Vol. 110, Iss. 15, pp. 2438-2454.e8
Open Access | Times Cited: 38
Ketamine and serotonergic psychedelics: An update on the mechanisms and biosignatures underlying rapid-acting antidepressant treatment
Jenessa N. Johnston, Bashkim Kadriu, Josh Allen, et al.
Neuropharmacology (2023) Vol. 226, pp. 109422-109422
Open Access | Times Cited: 32
Memantine: Updating a rare success story in pro-cognitive therapeutics
Parisa Karimi Tari, Chris G. Parsons, Graham L. Collingridge, et al.
Neuropharmacology (2023) Vol. 244, pp. 109737-109737
Open Access | Times Cited: 27
Esketamine: Less Drowsiness, More Analgesia
G. Mion, Sabine Himmelseher
Anesthesia & Analgesia (2024)
Closed Access | Times Cited: 9
Effect fingerprinting of new psychoactive substances (NPS): What can we learn from in vitro data?
Laura Hondebrink, Anne Zwartsen, Remco H.S. Westerink
Pharmacology & Therapeutics (2017) Vol. 182, pp. 193-224
Open Access | Times Cited: 76
The pharmacology of tacrine at N -methyl- d -aspartate receptors
Martin Hořák, Kristína Holubová, Eugenie Nepovimová, et al.
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2017) Vol. 75, pp. 54-62
Closed Access | Times Cited: 63
Pharmacological Investigations of the Dissociative ‘Legal Highs’ Diphenidine, Methoxphenidine and Analogues
Jason Wallach, Heather Kang, Tristan Colestock, et al.
PLoS ONE (2016) Vol. 11, Iss. 6, pp. e0157021-e0157021
Open Access | Times Cited: 61
Overlap in the neural circuitry and molecular mechanisms underlying ketamine abuse and its use as an antidepressant
Saurabh S. Kokane, Ross J. Armant, Carlos A. Bolaños‐Guzmán, et al.
Behavioural Brain Research (2020) Vol. 384, pp. 112548-112548
Open Access | Times Cited: 51
Low Doses of Psilocybin and Ketamine Enhance Motivation and Attention in Poor Performing Rats: Evidence for an Antidepressant Property
Guy A. Higgins, Nicole K. Carroll, Matthew A. Brown, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 48
Ketamine as a therapeutic agent for depression and pain: mechanisms and evidence
Subha Subramanian, Simon Haroutounian, Ben Julian A. Palanca, et al.
Journal of the Neurological Sciences (2022) Vol. 434, pp. 120152-120152
Closed Access | Times Cited: 33
Structural insights into NMDA receptor pharmacology
Changping Zhou, N. Tajima
Biochemical Society Transactions (2023) Vol. 51, Iss. 4, pp. 1713-1731
Open Access | Times Cited: 19
MK-801 and cognitive functions: Investigating the behavioral effects of a non-competitive NMDA receptor antagonist
Anna Janus, Klaudia Lustyk, Karolina Pytka
Psychopharmacology (2023) Vol. 240, Iss. 12, pp. 2435-2457
Open Access | Times Cited: 18
GluN2D N-Methyl-D-Aspartate Receptor Subunit Contribution to the Stimulation of Brain Activity and Gamma Oscillations by Ketamine: Implications for Schizophrenia
Kiran Sapkota, Zhihao Mao, Paul Synowicki, et al.
Journal of Pharmacology and Experimental Therapeutics (2015) Vol. 356, Iss. 3, pp. 702-711
Open Access | Times Cited: 61
Page 1 - Next Page

Scroll to top